This publication summarises a recent Auckland presentation by Associate Professor Chris Baker at the Novartis sponsored Rheumatology and Dermatology Dinner Meeting. A/P Baker discussed the prevalence of psoriatic arthritis (PsA) and its contribution to disease burden in patients with psoriasis, patient-directed treatments in those with psoriasis/PsA and other comorbidities, and the utility, efficacy and safety of IL-17 inhibitors in this group of patients. He also presented a difficult case of psoriasis and PsA demonstrating the importance of early intervention and treatment to target in moderate-to-severe psoriasis. This resource was created with unconditional funding from Novartis NZ Ltd.
Please login below to download this issue (PDF)